Cardinality Matching Study of Early v.s. Delayed VV ECMO in Severe Respiratory Failure

Acute Respiratory Failure Clinical Trial

Official title:

Cardinality Matching Study of Early v.s. Delayed VV ECMO in Severe Respiratory Failure

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03981393
• Other study ID #: ECMO-002
• Status: Completed
• Start date: December 1, 2011
• Est. completion date: March 31, 2018

Study information

• Verified date: April 2021
• Source: University of Cambridge
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Clinical reasoning and recent data suggest that early use of venovenous extracorporeal membrane oxygenation in refractory respiratory failure may confer a survival advantage.

This retrospective matched study will assess whether patients who received VV ECMO at less severe hypoxaemia had differing outcomes to those who received ECMO with very severe hypoxaemia.

Description:

VV ECMO is increasingly used in refractory respiratory failure. Despite advances in lung protective ventilation strategies, patients who have severe respiratory failure often develop complications from mechanical ventilation, including volutrauma and barotrauma. ECMO allows gas exchange to occur extracorporeally and may reduce the potential burden of iatrogenic lung injury by allowing a reduction of volume and pressure support - a 'lung rest' strategy. It is theorised that earlier intitiation of ECMO may allow for better outcomes, as there will have been less time for iatrogenic lung injury to occur.

The UK ECMO registry has been collected of patients treated under the NHS England commissioned respiratory ECMO service since 2011. This study has been previously registered and publication is intended shortly.

Patients will be extracted from this registry if they received VV ECMO. Propensity matching scores will be created and patients will be stratified into groups of 'early' vs 'delayed' ECMO, based on their probability of being in either group.

Patients will be divided into cohorts based on the median PaO2/FiO2 ratio at decision to cannulate ('less severe hypoxaemia') and ('very severe hypoxaemia'). Matched cohorts will be created correcting for key confounding factors (age, primary diagnosis, duration of pre-ECMO ventilation and PaCO2), using cardinality matching (a novel technique described by Zubizaretta et al. in 2014) and traditional propensity-score-based methods.

The technique with greater balance and statistical power (as defined by sample size) will be selected for the primary analysis.

Further analyses will assess the relationship between hypoxaemia at decision-to-cannulate and confounding factors as above.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 667
• Est. completion date: March 31, 2018
• Est. primary completion date: December 31, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years and older

Eligibility

Inclusion Criteria:

• Patients included in the UK ECMO registry (see previous registration; NCT number awaited; protocol ECMO-001)

• Patients with VV ECMO

Exclusion Criteria:

• Patients with inadequate or missing data for creation of propensity score models.

Related Conditions & MeSH terms

• Acute Respiratory Failure
• ECMO
• Respiratory Insufficiency

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
University of Cambridge

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Survival to ECMO ICU discharge	Percentage of patients alive at discharge from the ICU at the specialist ECMO centre	Up to 90 days.
Secondary	Duration of ECMO treatment	Duration spent supported by active ECMO treatment.	Up to 90 days.